A hidden genetic flaw could disarm aggressive cancers

Introduction: when a hidden weakness becomes a doorway

A California discovery worth pausing over

Researchers at UCLA Health have just published, in the journal Proceedings of the National Academy of Sciences (PNAS), a finding that deserves careful attention rather than easy excitement: a critical dependency on a protein called E2F3 in some of the most aggressive cancers that exist, small-cell neuroendocrine cancers, according to UCLA Health and ScienceDaily.

This type of cancer notably affects the lung, the prostate and the ovary, and it has earned a reputation for being particularly hard to treat once it has escaped hormone therapies or first-line treatment. What the American researchers found is a precise structural vulnerability in these tumors, a flaw that could, with caution, be exploited.

Why this story goes beyond scientific jargon

I know the name E2F3 means nothing to most readers, and that's fine: it's a regulatory protein that controls cell division. The essential point to remember is that in normal cells, a gene called RB acts as a brake on that division. When this brake disappears, as is the case in these aggressive cancers, the cell becomes oddly dependent on E2F3 to keep multiplying.

It's this dependency, which scientists call synthetic lethality, that opens a therapeutic avenue: if you strip away from the tumor the very thing it relies on to compensate for the loss of its natural brake, it collapses, while healthy cells come through in far better shape.

The RB gene, the brake that cancer knows how to disconnect

A cellular guardian taken out of service

The RB gene, short for retinoblastoma, is one of the most studied tumor suppressor genes in cancer research over the past decades. Its normal function is to prevent a cell from dividing out of control, a bit like a parking brake that keeps a car from rolling down a hill. In many small-cell neuroendocrine cancers, this brake is simply absent or disabled.

This absence is not good news in itself, quite the opposite, since it allows the tumor to proliferate more freely. But the researchers led by Dr. Owen N. Witte, a respected figure at the UCLA Health Jonsson Comprehensive Cancer Center, wanted to understand what the cancer cell had to do to compensate for that loss, and that's where the E2F3 lead emerged.

A solid research team behind the discovery

The study was led by Dr. Owen N. Witte, holder of the Presidential Chair in Developmental Immunology and founding director emeritus of the UCLA Broad Stem Cell Research Center, with Dr. Evan Abt, assistant professor of molecular and medical pharmacology at UCLA's David Geffen School of Medicine, as first author.

About a dozen other researchers contributed to this work, including Liang Wang, Grigor Varuzhanyan, Jack Freeland, Tian He and Thomas G. Graeber, which speaks to the scale of the collective effort needed to isolate this precise mechanism amid the biological complexity of a cancer cell.

Drugs already on the market, a precious advantage

The unexpected role of DHODH

The most promising part of this discovery may be that researchers identified an enzyme called DHODH, whose inhibition lowers levels of E2F3 in tumor cells. And inhibitors of this enzyme already exist, approved by the American FDA for years to treat autoimmune diseases.

These two drugs, leflunomide and teriflunomide, have long been used against rheumatoid arthritis and multiple sclerosis. Their safety profile is therefore already well documented in humans, which could considerably speed up the path to clinical trials in oncology, compared with an entirely new molecule that would have to start from scratch.

What this changes concretely for clinical research

Reusing an already-approved drug for a new indication, a practice researchers call drug repurposing, generally saves several years on the regulatory timeline, since questions of toxicity and safe dosing are already largely resolved.

Earlier work, published notably in the journal iScience, had already shown that teriflunomide and leflunomide could act in synergy with standard chemotherapies in small-cell lung cancers, which strengthens the consistency of this new lead with prior, independent observations.

Small-cell neuroendocrine cancers, a formidable adversary

A cancer known for resisting treatment

Small-cell neuroendocrine cancers are not simply rare variants: they represent a category of particularly aggressive tumors, capable of growing quickly and developing resistance to the hormone therapies used as first-line treatment, notably in advanced prostate cancer.

It is precisely this ability to bypass existing therapies that makes the search for new biological targets so urgent. When a prostate cancer initially treated with hormone therapy evolves into this neuroendocrine form, the prognosis worsens seriously, and treatment options become markedly more limited.

Three organs affected, one shared mechanism

What makes this discovery potentially significant is that the mechanism identified affects tumors that arise in very different organs, the lung, the prostate and the ovary, yet share this same dependency on E2F3 once the RB gene is lost.

A biological mechanism common to several types of cancer opens up the possibility, still theoretical at this stage, of a treatment that would not be limited to a single organ, which would represent a meaningful efficiency gain for pharmaceutical research as a whole.

What science cannot yet promise

From the lab to the patient, a long road still ahead

It would be dishonest to suggest that this discovery will translate tomorrow morning into a new treatment available in the clinic. The results published in PNAS come from preclinical studies, and the move toward clinical trials in humans, with all the methodological rigor that entails, will take time.

Even with the advantage of drugs already approved for other indications, it will still need to be shown, through controlled trials, that leflunomide and teriflunomide are truly effective and safe specifically against these neuroendocrine cancers, at dosages that remain to be precisely determined.

Measured hope rather than a miracle promise

I categorically refuse to present this discovery as a miracle cure, a stance I consider irresponsible whenever cancer is involved, a disease that has already seen too many premature announcements followed by disappointment for patients and their families.

What makes this news interesting is its methodological soundness and the credibility of the team behind it, not the promise of an immediate cure. It's one step among many in a long race, not a finish line.

California's research ecosystem, a constant engine of innovation

UCLA, a top-tier biomedical research hub

This discovery fits into UCLA's long tradition of top-level biomedical research, an institution that has produced, over the decades, major advances in immunology, stem cell biology and oncology, driven by figures such as Dr. Owen N. Witte.

The UCLA Broad Stem Cell Research Center, of which Witte is founding director emeritus, illustrates this American capacity to fund and sustain, over the long term, foundational research programs whose clinical payoff sometimes only materializes after several years, or even decades, of patient work.

A reminder of the importance of long-term scientific funding

This kind of discovery never falls out of the sky: it rests on stable funding for basic research, often public or philanthropic, which allows teams like Dr. Evan Abt's to pursue leads that don't necessarily produce spectacular short-term results.

At a time when biomedical research budgets are regularly the subject of political debate in the United States, this discovery is a useful reminder of why continued investment in basic science remains indispensable, even when its fruits are only harvested years later.

What this discovery means for patients today

No immediate change in treatment

For patients currently diagnosed with a small-cell neuroendocrine cancer, it is essential to understand that this discovery does not, at this stage, change standard treatment protocols. No clinical trial has yet been publicly announced to test leflunomide or teriflunomide specifically for this indication.

This is an important distinction to make, because I know that patients and their loved ones, in a legitimate search for hope, might be tempted to ask their oncologist for these drugs based solely on this scientific publication, a move that would be premature without rigorous clinical oversight.

Why this lead still deserves close attention

Despite these necessary caveats, this discovery deserves to be followed closely in the coming months and years, because the combination of a well-characterized biological mechanism and already-approved drugs historically represents one of the fastest paths toward new clinical trials in oncology.

Patients and cancer advocacy groups would do well to keep an eye on clinical trial registries in the months ahead, to see whether this lead does in fact translate into formal research protocols in humans.

Comparing this advance to other recent breakthroughs in oncology

A broader trend toward precision medicine

This discovery fits into a broader trend in modern oncology, that of precision medicine, which seeks to identify specific biological vulnerabilities rather than applying broad, general treatments that indiscriminately affect both healthy and cancerous cells.

This approach has already transformed the treatment of certain breast, lung and leukemia cancers over the past twenty years, by identifying precise mutations or dependencies that allow treatment to be targeted with far more finesse than before.

Why synthetic lethality keeps gaining ground

The concept of synthetic lethality, applied here to the RB-E2F3 pairing, has already proven itself elsewhere in oncology, notably with the PARP inhibitors used against certain breast and ovarian cancers carrying BRCA mutations.

This approach keeps gaining ground because it allows cancer cells to be struck selectively while relatively sparing healthy tissue, reducing the often severe side effects associated with traditional chemotherapies.

The questions that remain open going forward

Dosage and safety still need to be worked out

A crucial question remains unanswered at this stage: at what dosage would leflunomide or teriflunomide need to be administered to achieve a meaningful anticancer effect, and would that dosage be compatible with an acceptable safety profile over a treatment duration for oncology that could be longer than for an autoimmune disease.

These precise pharmacological questions can only be resolved through early-phase clinical trials, whose rigorous design will necessarily take time even before patient recruitment begins.

The real scale of clinical benefit still needs to be shown

Finally, it remains to be demonstrated, in real patients and not just in the lab, the real scale of clinical benefit this approach could bring, whether in terms of overall survival, quality of life or control of tumor progression.

It is this stage, the longest and most methodologically demanding, that will determine whether this promising discovery translates, several years from now, into a concrete change in the care of patients with these aggressive cancers.

What this story says about medical research in general

Science advances in small steps, rarely spectacular ones

This discovery illustrates well how medical research actually progresses: not through sudden, dramatic breakthroughs the way movies like to portray it, but through a patient accumulation of precise knowledge about complex molecular mechanisms.

The work of Dr. Owen N. Witte and his team, carried out over several years, even decades, to arrive at this fine-grained understanding of the relationship between RB and E2F3, speaks to this often-ignored reality, one the general public, eager to see miracle cures announced overnight, tends to overlook.

A lesson in patience for patients and the public

I think there is a lesson in patience to draw from this story for the public at large: the fight against cancer moves forward, concretely, year after year, even if progress doesn't always immediately translate into new treatments available at the pharmacy.

It's this patience, combined with a critical eye toward announcements that sound too good to be true, that allows one to follow scientific news with a gaze that is both curious and clear-eyed, without falling into either total cynicism or naive enthusiasm.

The potential impact on families affected by these cancers

Restoring a bit of hope without false promises

For families caring for a loved one with a small-cell neuroendocrine cancer, this kind of scientific news, even preliminary, can offer a breath of fresh air in what is often a grueling journey, provided it isn't turned into a promise it cannot keep.

I believe deeply that it's possible to communicate realistic hope without lying by omission about the remaining timelines and uncertainties, a fine but essential line to respect when writing about a subject as sensitive as cancer.

The role of the media in communicating science

This story also illustrates the responsibility resting on the media, including this outlet, in how medical advances are relayed: between the total silence that would deprive the public of useful information and the sensationalism that would betray scientific reality, an honest balance must always be sought.

That is the balance I have tried to strike throughout this commentary, insisting equally on this discovery's real potential and on its current limits, still numerous, before it changes the life of even a single patient.

Why basic research deserves our collective attention

An investment that crosses national borders

Although this research is American, carried out at UCLA and published in a leading American journal, its potential payoff, if confirmed in the years ahead, would benefit patients across the Western world, including here, in Canada and in Quebec.

It's a useful reminder that cutting-edge biomedical research remains largely a collective Western effort, where American, European and Canadian discoveries enrich one another, a scientific collaboration that deserves to be protected and funded over the long haul.

What this means for the years ahead

If this lead on E2F3 and DHODH holds up in future clinical trials, it could be added to the already long list of successful drug repurposing examples, giving a useful second life to medicines that are already well known.

It's this prospect, still uncertain but scientifically grounded, that makes this UCLA discovery worth watching closely in the months and years ahead, without rushing to conclusions or falling into premature disappointment.

The importance of international scientific cooperation

Scientific journals that enable peer verification

The publication of this study in PNAS, one of the most respected scientific journals in the world, guarantees that it went through a rigorous peer review process, in which other independent experts examined the methodology and the results before public release.

This process, though imperfect, remains one of the best safeguards the scientific community has to filter solid research from work with methodological flaws too significant to be published as is.

A discovery that benefits science worldwide

Once published, this discovery becomes accessible to researchers everywhere, who can try to reproduce it, build on it or challenge it, a normal and healthy process within the scientific method that, over time, strengthens the reliability of conclusions that survive this collective scrutiny.

It is this collaborative, international dimension of science that should reassure us against the temptations of scientific isolationism sometimes seen in certain countries, including rivals of the West.

What this advance reveals about the future of the fight against cancer

A battle now won gene by gene

This discovery about E2F3 confirms a deep shift in how Western medicine approaches cancer: the goal is no longer simply to destroy diseased cells en masse, but to understand precisely their weak points, gene by gene, protein by protein, in order to strike with surgical precision rather than a chemical hammer.

This methodological transformation, driven by institutions such as UCLA, MD Anderson Cancer Center or Memorial Sloan Kettering, illustrates the ability of North American and Western research to stay at the global forefront of molecular oncology, a highly competitive field where Europe and Asia are also investing considerable sums.

A scientific race that ultimately benefits patients

This international competition in cancer research, far from being a problem, is in fact a powerful engine of innovation: every lab, whether American, European, Japanese or South Korean, pushes the others to speed up their own work, in a dynamic that ultimately benefits patients everywhere, including those who will never hear the name Dr. Owen N. Witte or UCLA.

It is this healthy dynamic of scientific competition, paired with the open sharing of results through journals like PNAS, that fundamentally sets the Western model of biomedical research apart from other, more closed or centralized models, where the spread of knowledge remains subject to political considerations rather than purely scientific ones.

Conclusion: a solid advance, not an instant revolution

What to take away from this discovery

The discovery of the dependency on E2F3 in small-cell neuroendocrine cancers stripped of the RB gene represents a solid scientific advance, driven by a credible team at UCLA Health, with the rare advantage of potentially relying on drugs already approved by the FDA.

This is neither an instant revolution nor an unimportant piece of news: it is exactly the kind of methodical, documented and well-sourced progress that deserves to be followed closely, without tipping into excessive enthusiasm or sterile cynicism.

The next chapter to watch

The coming months will tell whether this lead results in the announcement of formal clinical trials testing leflunomide or teriflunomide specifically against these aggressive cancers, a pivotal step that will determine how quickly this discovery could, one day, concretely change the lives of patients across the West.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my verification method

I sign this commentary as a columnist who strives to make medical science accessible without ever promising more than the data allows. My method relies on the official release from UCLA Health, on ScienceDaily and on the scientific publication available via PubMed and PMC, cross-checking the biographical information of the researchers cited against UCLA's institutional pages.

I am not a physician or a molecular biology researcher, and I therefore rely on the plain-language explanations provided by the institutions themselves rather than an independent expert reading of the full scientific paper.

What I cannot guarantee

I cannot guarantee that this discovery will translate into a clinical treatment available within a specific timeframe, nor can I predict the results of any future clinical trials on leflunomide or teriflunomide for this indication. This commentary reflects the state of public knowledge at the time of writing, in early July 2026.

Sources

Primary sources

UCLA Health, official release on the discovery of the E2F3 vulnerability — June 2026

ScienceDaily, hidden genetic weakness in aggressive cancers — June 26, 2026

PNAS via PMC, full study on synthetic lethality between RB loss and E2F3 inhibition — March 20, 2026

Secondary sources

UCLA Broad Stem Cell Research Center, presentation of the discovery — June 2026

PubMed, reference for the study on E2F3 dependency — 2026

iScience via PMC, synergy of teriflunomide and leflunomide with chemotherapy in small-cell lung cancer — May 27, 2024